Top 5 vaccines by 2020

Though it picked up some steam in 2014, Prevnar--anticipated to be the world's top shot in 2020--showed some signs of slowing in this year's EvaluatePharma World Preview 2015 report. According to the analysts, the shot--which last year was expected to haul in $6.08 billion in sales, will take in $5.83 billion in 2020. Still, though, enough to make it far and away the world's top vaccine in 5 years.

Last year, EP estimated that Pentacel, Gardasil, Fluzone and Pediarix would round out the top 5, but their estimates have shuffled a bit this year. Now, by 2020, the analysts predict Gardasil to take No. 2 with $2.52 billion in sales; Fluzone in No. 3 with $2.03 billion in sales; Pentacel at No. 4 with $1.68 billion in sales; and Pediarix in the fifth spot with $1.54 in 2020 sales.

All of the shots--minus Gardasil--showed signs of slowing, with the sharpest CAGR drop of 4% in Pentacel's case. Gardasil, last year expected to grow just 2%, is estimated in this year's report to post 4% growth through 2020.

Please review the list and feel free to comment by email. -- Amirah Al Idrus (email) and Eric Sagonowsky (email)

The top 5 vaccines by 2020
Vaccine & Company
Use
2014 Sales (billions)
2020 Sales (billions)
CAGR 2014-20

Pneumococcal infection
$4.297
$5.83
5%

Human papillomavirus (HPV)
$2.03
$2.52
4%

Influenza
$1.72
$2.03
3%

Diphtheria, pertussis/whooping cough; tetanus; polio; Haemophilus influenzae type B
$1.53
$1.68
2%

Diphtheria; tetanus; pertussis/whooping cough; hepatitis B; polio
$1.36
$1.54
2%
Courtesy of EvaluatePharma

 

Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.